Angiogenesis in Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 46-49

  Terpos, Evangelos ^a   Tasidou, Anna ^b   Kastritis, Efstathios ^a   Eleftherakis Papaiakovou, Evangelos ^a   Gavriatopoulou, Maria ^a   Migkou, Magdalini ^a   Dimopoulos, Meletios Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Angiogenin; Angiopoietins; Macrophage inflammatory protein 1 alpha; Mast cells; Vascular endothelial growth factor; Waldenstr m

Indexed keywords

ANGIOGENESIS; ARTICLE; BONE MARROW; HUMAN; MICROVASCULATURE; MONOCLONAL IMMUNOGLOBULINEMIA; WALDENSTROEM MACROGLOBULINEMIA; BLOOD; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENIC PROTEIN; CYTOKINE; VASCULOTROPIN;

ANGIOGENIC PROTEINS; BONE MARROW; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649544376     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.011     Document Type: Article

References (25)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:1564-77.
2. Kriangkum J, Taylor BJ, Treon SP, et al. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104:2134-42.
3. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008; 112:4683-9.
4. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28:560-4.
5. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58:491-504.
6. Fam NP, Verma S, Kutryk M, et al. Clinician guide to angiogenesis. Circulation 2003; 108:2613-8.
7. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16:159-78.
8. Anargyrou K, Dimopoulos MA, Sezer O, et al. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 2001; 49:677-89.
9. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concen-trations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 137:560-8.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
11. Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-10.
12. Rajkumar SV, Hayman S, Greipp PR. Angiogenesis in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:262-4.
13. Padr T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95:2637-44.
14. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82.
15. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104:2224-34.
16. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-65.
17. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56:4625-9.
18. De Palma M, Venneri MA, Galli R. Tie2 identifies h hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211-26.
19. Terpos E, Anagnostopoulos A, Kastritis E, et al. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia. Br J Haematol 2006; 133:301-4.
20. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992; 3:73-9.
21. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood 1995; 86:2488-93.
22. Ribatti D, Vacca A, Nico B, et al. The role of mast cells in tumour angiogenesis. Br J Haematol 2001; 115:514-21.
23. Tassone P, Neri P, Kutok JL, et al. A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood 2005; 106:1341-5.
24. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30:265-9.
25. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-7.